Sign in
Taking people in United StatesNo phase

Gluten detection devices and remote care for newly diagnosed celiac disease

Tests gluten detection tools plus telemedicine in adults newly diagnosed with celiac disease.

Key facts

Who runs it
Columbia University
Where
Boston, Chicago, Nashville, and New York, United StatesSee the 4 sites
Trial code
Registry title
Gluten Technology and Education for Celiac Health
Status
Recruiting
People taking part
200 people, planned
Started
8 Oct 2024
Expected to end
31 Aug 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Gluten detection technology
  • Continuous telemedicine monitoring
Record updated
10 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults recently diagnosed with celiac disease. It tests gluten detection tools added to telehealth dietitian follow-up.

Age
18 to 75 years
Sex
All genders can join.
Disease stage
Celiac disease confirmed by a blood test and a biopsy of the small bowel (Marsh 3 changes), diagnosed within 4 months of screening.
Earlier treatment
People cannot join if they currently use a gluten detection test of urine or stool.
Biomarker or test result
Celiac disease shown by blood test (serology) and duodenal biopsy with Marsh 3 histology.

Main reasons for not taking part

  • Pregnant now or planning a pregnancy during the study
  • Not planning to follow a gluten-free diet
  • Taking part in another trial of an experimental drug
  • Not willing to use gluten detection technology

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Any gender; Age 18-75 years
  • Celiac disease diagnosis by serology and duodenal biopsy (corresponding to •Marsh 3 histology), adequate sampling and interpretable villus height to crypt depth ratio upon review by our study pathologist
  • Diagnosed with celiac disease within 4 months of initial study screening
  • Willingness to use gluten-detection technology
  • Not currently using a gluten detection technology that tests for gluten in urine or stool

Who cannot take part

  • Concurrent participation in a clinical trial of an experimental pharmacologic agent (for any condition)
  • Currently pregnant or planning to become pregnant during the study
  • Not planning to follow a gluten-free diet

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United States

  • Beth Israel Deaconess Medical CenterBoston, United StatesContact: Jocelyn Silvester, MD, PhDTaking people
  • University of Chicago Medical CenterChicago, United StatesContact: Sonia Kupfer, MDTaking people
  • Vanderbilt University Medical CenterNashville, United StatesContact: Dawn Adams, MDTaking people
  • Columbia University Irving Medical CenterNew York, United StatesContact: Benjamin Lebwohl, MD, MSTaking people

About the trial

What the trial wants to find out

The investigators propose to plan for a multi-center randomized controlled trial (M-RCT) to test the effectiveness of novel gluten detection technologies as an adjunct to telemedicine to manage celiac disease in newly diagnosed adults. If successful, the proposed intervention will improve mucosal recovery, promote a shift in current practice of celiac disease management toward long-term monitoring, and represent a significant step toward reducing the severe physical and psychological consequences of celiac disease.

The 2 groups in the trial

  • Standard of CareExisting treatment, for comparison

    Participants will be provided with continuous Telehealth dietitian follow-up

    Treatment: Continuous telemedicine monitoring

  • Standard of Care Plus TechnologyTreatment being tested

    In addition to standard of care, participants will be provided with gluten detection technology so as to assist in navigating the gluten-free diet.

    Treatment: Gluten detection technology and Continuous telemedicine monitoring

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Gluten Technology and Education for Celiac Health
Plain-language title
Gluten detection devices and remote care for newly diagnosed celiac diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT06059716, who can take part
Record updated
10 June 2026